GPR162, G protein-coupled receptor 162, 27239

N. diseases: 51; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0010068
Disease: Coronary heart disease
Coronary heart disease 		0.030 Biomarker disease BEFREE Administration of fenofibrate (300 mg/d) to 16 patients with coronary artery disease resulted in a marked increase in plasma apo A-II concentrations (0.34 +/- 0.11 to 0.45 +/- 0.17 grams/liter; P < 0.01). 7635967 1995
CUI: C1956346
Disease: Coronary Artery Disease
Coronary Artery Disease 		0.030 Biomarker disease BEFREE Administration of fenofibrate (300 mg/d) to 16 patients with coronary artery disease resulted in a marked increase in plasma apo A-II concentrations (0.34 +/- 0.11 to 0.45 +/- 0.17 grams/liter; P < 0.01). 7635967 1995
CUI: C1956346
Disease: Coronary Artery Disease
Coronary Artery Disease 		0.030 Biomarker disease BEFREE These data indicate that the MspI RFLP 3' to the apo A-II gene is somewhat more frequent in the CAD group. 1352975 1992
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction 		0.030 Biomarker disease BEFREE The genetic and cultural heritability of serum cholesterol and triglyceride concentrations, as well as of the concentrations of low and high density lipoprotein cholesterol and serum apolipoproteins A-I, A-II and B, were estimated by path analysis in families selected through probands with premature myocardial infarction and in families randomly selected from the general population. 3730041 1986
CUI: C0010068
Disease: Coronary heart disease
Coronary heart disease 		0.030 AlteredExpression disease BEFREE Serum apolipoprotein A-I, A-II and B levels and their discriminative values in relatives of patients with coronary artery disease. 6430307 1984
CUI: C1956346
Disease: Coronary Artery Disease
Coronary Artery Disease 		0.030 AlteredExpression disease BEFREE Serum apolipoprotein A-I, A-II and B levels and their discriminative values in relatives of patients with coronary artery disease. 6430307 1984
CUI: C0040822
Disease: Tremor
Tremor 		0.020 GeneticVariation phenotype BEFREE This novel porcine pestivirus was first described in 2015 in the USA, where it has been associated with congenital tremor type A-II in new-born piglets. 31835549 2019
CUI: C0041351
Disease: Tularemia
Tularemia 		0.020 GeneticVariation disease BEFREE Phylogenetic Analysis of Francisella tularensis Group A.II Isolates from 5 Patients with Tularemia, Arizona, USA, 2015-2017. 31002053 2019
CUI: C0040822
Disease: Tremor
Tremor 		0.020 GeneticVariation phenotype BEFREE Atypical porcine pestivirus (APPV) has been considered a novel pestivirus and causative agent of congenital tremor type A-II. 28710801 2018
CUI: C0004114
Disease: Astrocytoma
Astrocytoma 		0.020 Biomarker disease BEFREE Our analyses imply that the differences in age and survival between A II(WHO2007) and AA III(WHO2007) predominantly depend on the fraction of IDH-non-mutant astrocytomas in the cohort. 25962792 2015
CUI: C0017536
Disease: Giardiasis
Giardiasis 		0.020 GeneticVariation disease BEFREE We detected Encephalitozoon cuniculi genotypes I and II (7.5%), Enterocytozoon bieneusi genotype D and three novel genotypes (gorilla 1-3) (4.0%), Giardia intestinalis subgroup A II (2.0%) and Cryptosporidium bovis (0.5%) in gorillas, whereas in humans we found only G. intestinalis subgroup A II (2.1%). 23951255 2013
CUI: C0017536
Disease: Giardiasis
Giardiasis 		0.020 Biomarker disease BEFREE Intestinal growth and pathology of Giardia duodenalis assemblage subtype A(I), A(II), B and E in the gerbil model. 22216783 2012
CUI: C0004114
Disease: Astrocytoma
Astrocytoma 		0.020 GeneticVariation disease BEFREE Material and methods We examined 17 oligodendrogliomas (O II, 11 with LOH1p), 16 oligoastrocytomas (OA II, 5 with LOH1p) and 7 astrocytomas (A II, none with LOH1p). 18726700 2008
CUI: C0041351
Disease: Tularemia
Tularemia 		0.020 GeneticVariation disease BEFREE Tularemia is caused by two subspecies of Francisella tularensis, F. tularensis subsp. tularensis (type A) and F. tularensis subsp. holarctica (type B).F. tularensis subsp. tularensis is further subdivided into two genetically distinct populations (A.I and A.II) that differ with respect to geographical location, anatomical source of recovered isolates, and disease outcome. 18024683 2008
CUI: C0020557
Disease: Hypertriglyceridemia
Hypertriglyceridemia 		0.020 Biomarker phenotype BEFREE Overexpression of human apolipoprotein A-II (apo A-II) in mice induced postprandial hypertriglyceridemia and marked reduction in plasma HDL concentration and particle size [Boisfer et al.(1999) J. Biol.Chem.274, 11564-11572]. 11591143 2001
CUI: C0036202
Disease: Sarcoidosis
Sarcoidosis 		0.020 GeneticVariation disease BEFREE Our results showed a strong correlation between the uncommon TNF A II allele and sarcoidosis-associated erythema nodosum. 11411907 2001
CUI: C0036202
Disease: Sarcoidosis
Sarcoidosis 		0.020 Biomarker disease BEFREE The receptor binding assay suggested that specific binding of A-II to BALF macrophages was somewhat more prevalent in active sarcoidosis than in controls. 10207944 1999
CUI: C0206624
Disease: Hepatoblastoma
Hepatoblastoma 		0.020 AlteredExpression disease BEFREE In the HepG2 human hepatoblastoma cell line, both at-RA and 9-cis RA as well as the retinoid X receptor (RXR)-specific agonist LGD 1069, but not the RA receptor (RAR) agonist ethyl-p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-l-pro penyl]-benzoic acid (TTNPB), induce apo A-II mRNA levels. 8668150 1996
CUI: C0010054
Disease: Coronary Arteriosclerosis
Coronary Arteriosclerosis 		0.020 Biomarker disease BEFREE Administration of fenofibrate (300 mg/d) to 16 patients with coronary artery disease resulted in a marked increase in plasma apo A-II concentrations (0.34 +/- 0.11 to 0.45 +/- 0.17 grams/liter; P < 0.01). 7635967 1995
CUI: C0206624
Disease: Hepatoblastoma
Hepatoblastoma 		0.020 AlteredExpression disease BEFREE This increase in plasma apo A-II was due to a direct effect on hepatic apo A-II production, since fenofibric acid induced apo A-II mRNA levels to 450 and 250% of control levels in primary cultures of human hepatocytes and in human hepatoblastoma HepG2 cells respectively. 7635967 1995
CUI: C0342895
Disease: Fish-Eye Disease
Fish-Eye Disease 		0.020 Biomarker disease BEFREE Because LpA-I has been proposed to be more protective than LpA-I:A-II against atherosclerosis, this selective effect on the metabolism of LpA-I:A-II may provide a potential explanation why patients with classic LCAT deficiency and Fish-eye disease are not at increased risk for premature atherosclerosis despite markedly decreased levels of HDL cholesterol and apoA-I. 8282802 1994
CUI: C0020557
Disease: Hypertriglyceridemia
Hypertriglyceridemia 		0.020 Biomarker phenotype BEFREE Biochemical investigations showed hypoalphalipoproteinaemia (with a faint fast-moving HDL band on polyacrylamide gel gradient electrophoresis and small arcs of HDL2 and HDL3 of low mobility determined by agarose gel immunoelectrophoresis), low total cholesterol (3.5-4.9 mmol l-1), slightly decreased cholesteryl ester/total cholesterol ratio (0.52-0.63), extremely low HDL cholesterol (0.20-0.21 mmol l-1), mild hypertriglyceridaemia (1.94-3.80 mmol l-1), and striking deficiency in apo A-I and apo A-II (0.45-0.72, 0.08-0.16 g l-1, respectively). 1778223 1991
CUI: C0342895
Disease: Fish-Eye Disease
Fish-Eye Disease 		0.020 Biomarker disease BEFREE Similarly, concentrations of apolipoproteins A-I and A-II in the serum of FED subjects were only 10% of those in normal subjects. 3030583 1987
CUI: C0010054
Disease: Coronary Arteriosclerosis
Coronary Arteriosclerosis 		0.020 AlteredExpression disease BEFREE Serum apolipoprotein A-I, A-II and B levels and their discriminative values in relatives of patients with coronary artery disease. 6430307 1984
CUI: C0039292
Disease: Tangier Disease
Tangier Disease 		0.020 Biomarker disease BEFREE Plasma apolipoprotein concentrations in familial apolipoprotein A-I and A-II deficiency (Tangier disease). 6790903 1981